Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Lack of efficacy of an immunomodulatory macrolide in childhood HIV related bronchiectasis: A randomised, placebo-controlled trial
Journal of Antivirals and Antiretrovirals, Volume 5, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
Background: The epidemic of human immunodeficiency virus (HIV)-1 infection has resulted in a large number of children suffering from respiratory morbidity in South Africa. One of the outcomes of recurrent chest infections and TB is HIV-related bronchiectasis. Introduction: We conducted a randomised, double-blind, placebo-controlled trial to assess the efficacy of low dose erythromycin in reducing the number of pulmonary exacerbations. Methods: We randomly assigned 31 HIV-infected children with radiologically confirmed bronchiectasis, to receive either erythromycin (17) or matching placebo (14) for a period of 52 weeks. The primary outcome was the number of exacerbations documented over the 52 weeks, in each study arm, after randomisation. Results: There was no difference in the number of exacerbations in the participants receiving erythromycin versus those receiving placebo (2.14 ± 1.29 vs. 2.18 ± 1.59 per year; p=0.17). There was an improvement (although not statistically significant) in both FEV1 % predicted and FVC % predicted (56.0% predicted ± 15.1 to 68.0% predicted ± 21.0 and 53.5% predicted ± 13.6 to 62.5% predicted ± 13.6; p=0.31) in the erythromycin and placebo arm, respectively. Erythromycin did not impact the levels of pro-inflammatory and anti-inflammatory cytokines (all p>0.05). Conclusion: Administration of HAART and adjunctive care, which includes airway clearance and treatment of exacerbations, in children with HIV-related bronchiectasis is associated with improvement in pulmonary function tests and IL-8, with no additional benefit from the use of erythromycin. © 2013 Masekela R, et al.
Authors & Co-Authors
Masekela, Refiloe R.
South Africa, Pretoria
Steve Biko Academic Hospital
Anderson, Ronald
South Africa, Pretoria
University of Pretoria
Gongxeka, Harlem
South Africa, Pretoria
University of Pretoria
Steel, Helen C.
South Africa, Pretoria
University of Pretoria
Becker, Pieter J.
South Africa, Pretoria
Steve Biko Academic Hospital
South Africa, Tygerberg
South African Medical Research Council
Green, Robin John
South Africa, Pretoria
Steve Biko Academic Hospital
Statistics
Citations: 10
Authors: 6
Affiliations: 3
Identifiers
Doi:
10.4172/jaa.1000062
e-ISSN:
19485964
Research Areas
Disability
Infectious Diseases
Maternal And Child Health
Study Design
Case-Control Study
Study Locations
South Africa